RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Suzhou’s CStone Pharma acquired Greater China rights to a tri-specific PD-L1 antibody developed by Zurich’s Numab in exchange for funding R&D of the molecule through a Phase I clinical trial. ND021 is a late-preclinical molecule that targets PD-L1, 4-1BB, and human serum albumin (HSA). Because it activates T cells only when binding PD-L1 on tumor cells, ND021 is expected to avoid the liver toxicities of other 4-1BB-agonistic antibodies. CStone notes that once the Phase Ib trial is completed, it will have no other financial obligations for ND021.
Source: China Biotoday
